tbuckley/cabot-search huggingface dataset:
Lung Cancer Screening and Incidental Findings: A Research Agenda. An Official American Thoracic Society Research Statement
Authors: Louise M Henderson, Roger Y. Kim, Nichole T Tanner, Emily B. Tsai, Abbie Begnaud, Farouk Dako, Michael Gieske, Kimberly Kallianos, Ilana Richman, Lori C Sakoda, Ronald G Schwartz, Joseph Yeboah, Kwun M Fong, Stephen Lam, Pyng Lee, Mary Pasquinelli, Robert A. Smith, Matthew Triplette, Lynn T. Tanoue, M. Patricia Rivera
Journal: American Journal of Respiratory and Critical Care Medicine (2025)

Lung cancer screening with low-dose computed tomography (LDCT) may uncover incidental findings (IFs) unrelated to lung cancer. There may be potential benefits from identifying clinically significant IFs that warrant intervention and potential harms related to identifying IFs that are not clinically significant but may result in additional evaluation, clinician effort, patient anxiety, complications, and excess cost. To identify knowledge and research gaps and develop and prioritize research questions to address the approach to and management of IFs. We convened a multidisciplinary panel to review the available literature on IFs detected in lung cancer screening LDCT exams, focusing on variability and standardizing reporting, management of IFs, and evaluation of the benefits and harms of IFs, particularly cardiovascular-related IFs. We used a three-round modified Delphi process to prioritize research questions. This statement identifies knowledge gaps in (1) reporting of IFs, (2) management of IFs, and (3) identifying and reporting coronary artery calcification found on lung cancer screening LDCT. Finally, we present the panel's initial 36 research questions and the final 20 prioritized questions. This statement provides a prioritized research agenda to further efforts focused on evaluating, managing, and increasing awareness of IFs in lung cancer screening.
Lactate controls cancer stemness and plasticity through epigenetic regulation
Authors: Nguyen T B Nguyen, Sira Gevers, Rutger N U Kok, Lotte M Burgering, Hannah Neikes, Ninouk Akkerman, Max A Betjes, Marlies C Ludikhuize, Can Gulersonmez, Edwin C A Stigter, Yvonne Vercoulen, Jarno Drost, Hans Clevers, Michiel Vermeulen, Jeroen S van Zon, Sander J Tans, Boudewijn M T Burgering, Maria J Rodríguez Colman
Journal: Cell Metabolism (2025)

Tumors arise from uncontrolled cell proliferation driven by mutations in genes that regulate stem cell renewal and differentiation. Intestinal tumors, however, retain some hierarchical organization, maintaining both cancer stem cells (CSCs) and cancer differentiated cells (CDCs). This heterogeneity, coupled with cellular plasticity enabling CDCs to revert to CSCs, contributes to therapy resistance and relapse. Using genetically encoded fluorescent reporters in human tumor organoids, combined with our machine-learning-based cell tracker, CellPhenTracker, we simultaneously traced cell-type specification, metabolic changes, and reconstructed cell lineage trajectories during tumor organoid development. Our findings reveal distinctive metabolic phenotypes in CSCs and CDCs. We find that lactate regulates tumor dynamics, suppressing CSC differentiation and inducing dedifferentiation into a proliferative CSC state. Mechanistically, lactate increases histone acetylation, epigenetically activating MYC. Given that lactate's regulation of MYC depends on the bromodomain-containing protein 4 (BRD4), targeting cancer metabolism and BRD4 inhibitors emerge as a promising strategy to prevent tumor relapse.
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Authors: Stephane Champiat, Elena Garralda, Vladimir Galvao, Philippe A. Cassier, Carlos Gomez-Roca, Iphigenie Korakis, Peter Grell, Aung Naing, Patricia LoRusso, Romana Mikyskova, Nada Podzimkova, Milan Reinis, Kaissa Ouali, Andreu Schoenenberger, Joachim Kiemle-Kallee, Sascha Tillmanns, Richard Sachse, Ulrich Moebius, Radek Spisek, David Bechard, Lenka Palova Jelinkova, Irena Adkins, Aurelien Marabelle
Journal: Cell Reports Medicine (2025)

Nanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor βγ superagonist that stimulates natural killer (NK) and CD8+ T cells, thereby promoting an innate and adaptive anti-tumor inflammatory microenvironment in mouse tumor models either in monotherapy or combined with an anti-programmed cell death protein 1 (PD-1) antibody. In cynomolgus monkeys, a clinical schedule was identified, which translated into the design of a phase 1/1b clinical trial, AURELIO-03 (NCT04234113). In 51 patients with advanced/metastatic solid tumors, nanril increased the proportions of CD8+ T cells and NK cells in peripheral blood and tumors. It had a favorable safety profile when administered subcutaneously on days 1, 2, 8, and 9 of each 21-day cycle as monotherapy (0.25-15 μg/kg) or combined (1.5-12 μg/kg) with the anti-PD-1 pembrolizumab (200 mg). The most frequent treatment-emergent adverse events were pyrexia, injection site reactions, and chills. Furthermore, early clinical efficacy was observed, including in immune checkpoint blockade-resistant/refractory patients.
Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies
Authors: Sarah-Eve Lemay, Manon Mougin, Mélanie Sauvaget, Reem El Kabbout, Chanil Valasarajan, Keiko Yamamoto, Sandra Martineau, Andréanne Pelletier, Coralie Bilodeau, Yann Grobs, Alice Bourgeois, Charlotte Romanet, Sandra Breuils-Bonnet, Monica S. Montesinos, Min Lu, Huidong Chen, Mégan Gilbert, Charlie Théberge, François Potus, Soni Pullamsetti, Steeve Provencher, Sébastien Bonnet, Olivier Boucherat
Journal: Cell Reports Medicine (2025)

Highlights•AURKB expression in PASMC is upregulated in PAH•Inhibition of AURKB reduces PAH-PASMC proliferation and induces cellular senescence•Inhibition of AURKB improves established PAH in animal models and in PCLSs•Dual AURKB/p21 inhibition is more effective in reducing vascular remodeling in vivoSummaryDespite advances in treatment, the prognosis for patients with pulmonary arterial hypertension (PAH) remains dismal, highlighting the need for further therapeutic advances. By using RNA sequencing on pulmonary artery smooth muscle cells (PASMCs), functional enrichment, and connectivity map analyses, we identify Aurora kinase B (AURKB) as a candidate therapeutic target. We show that AURKB inhibition blocks cell cycle progression and reverses the gene signature of PAH-PASMCs. We also report that PAH-PASMCs that escape apoptosis acquire a senescence-associated secretory phenotype. In vivo, AURKB inhibition using barasertib improves hemodynamics in two preclinical models of established PAH by attenuating pulmonary vascular remodeling. A therapeutic effect is also observed in human precision-cut lung slices. Finally, we demonstrate that the combination of barasertib with a p21 attenuator is more effective in reducing vascular remodeling than either drug alone. These findings provide insight into strategies for therapeutic manipulation.Graphical abstract
Results of the phase I/II study and preliminary B cell gene signature of combined inhibition of glutamine metabolism and EGFR in colorectal cancer
Authors: Kristen K. Ciombor, Seong-Woo Bae, Jennifer G. Whisenant, Gregory D. Ayers, Quanhu Sheng, Todd E. Peterson, Gary T. Smith, Kangyu Lin, Saikat Chowdhury, Preeti Kanikarla Marie, Alexey Sorokin, Allison S. Cohen, Laura W. Goff, Dana B. Cardin, John Paul Shen, Scott Kopetz, Cathy Eng, Yu Shyr, Jordan Berlin, H. Charles Manning
Journal: Clinical Cancer Research (2025)

Abstract Purpose: EGFR-targeting monoclonal antibodies are essential for managing RAS WT metastatic colorectal cancer (mCRC), but their limited efficacy necessitates exploring immunological and metabolic factors influencing response. This study evaluated glutamine metabolism targeting with EGFR inhibition to identify response biomarkers in patients with prior anti-EGFR treatment progression. Experimental Design: We conducted a phase I/II trial in KRAS WT mCRC patients, combining panitumumab and CB-839, hypothesizing that dual inhibition of glutamine metabolism and MAPK signaling would enhance outcomes. As study correlatives, we investigated the B cell activation signature ‘Bscore’ and glutamine PET as potential treatment response biomarkers. Results: The combination of panitumumab and CB-839 was tolerable with manageable side effects, including Grade 4 hypomagnesemia in four patients, a known panitumumab-related event. Two patients achieved partial response (PR), and five had stable disease (SD), with a 41% disease control rate (DCR). Median progression-free survival (PFS) and overall survival (OS) were 1.84 and 8.87 months, respectively. A positive correlation between ‘Bscore’ and lesion size reduction suggested its association with clinical benefit (PR and SD). Lower ‘Bscore’ correlated with greater tumor avidity for glutamine by PET, indicating B cell activation sensitivity to glutamine depletion. Conclusions: The combination of CB-839 and panitumumab showed safety and promising preliminary responses, but the study closed early due to CB-839 development termination. The B cell activation signature ‘Bscore’ emerged as a potential biomarker for EGFR and glutaminase inhibition in mCRC, warranting further studies. These findings suggest opportunities to improve immune response and therapies in glutaminolysis-dependent tumors.
Serum chloride concentration and outcomes in adults receiving intravenous fluid therapy with a balanced crystalloid solution or 0.9% sodium chloride
Authors: Mahesh Ramanan, Naomi Hammond, Laurent Billot, Anthony Delaney, Anthony Devaux, Simon Finfer, Qiang Li, Sharon Micallef, Balasubramanian Venkatesh, Paul J Young, John Myburgh
Journal: Intensive Care Medicine (2025)
An updated systematic review, meta-analysis and trial sequential analysis of the efficacy and safety of en bloc transurethral resection vs. conventional transurethral resection for non-muscle-invasive bladder tumor
Authors: Zhunan Xu, Qihua Wang, Li Bing, Xuexue Hao, Congzhe Ren, Xiangyu Chen, Li Liu, Xiaoqiang Liu
Journal: International Journal of Surgery (2025)
Spatial biology – unravelling complexity within the glioblastoma microenvironment
Authors: Stephen D. Robinson, Chrysa Filippopoulou, Simoni Besta, Mark Samuels, Andrea L. Betrán, Maha Abu Ajamieh, Viviana Vella, William Jones, Georgios Giamas
Journal: Trends in Molecular Medicine (2025)

HighlightsThe ability to understand molecular differences at a single cell level, and with increasing granularity, through spatial profiling is starting to unravel the complexity of the glioblastoma tumour microenvironment (TME).Identifying variations in the spatial distribution of different cell types is providing novel insights into tumour biology and leading to the identification of TME-based tumour subtypes.Greater understanding of the relationships between different cell types, and the identification of rare, but biologically important, cell states is identifying new biomarkers for predicting an individual's response to treatment and suggesting novel resistance mechanisms.AbstractThe advent and refinement of state-of-the-art spatial biology technologies have facilitated analysis that combines the advantages of high-throughput single cell analysis with techniques that preserve tissue architecture. This combination of cellular phenotyping with retained spatial context provides a much greater understanding of cellular interactions within the tumour microenvironment (TME). For glioblastoma, with its significant intra-tumoural heterogeneity, cellular plasticity, and complex TME, appreciating and understanding these spatial patterns may prove key to improving patient outcomes. This review examines the advances in spatial biology techniques, discusses how these methodologies are being applied to study glioblastoma, and explores how spatial information improves understanding of the TME. Ultimately, it is this spatial context that will accelerate the identification of more effective treatments for glioblastoma.
Dynamic changes in 3D chromatin structure during male gametogenesis in Arabidopsis thaliana
Authors: Zhihan Song, Qimin Xia, Minqi Yang, Tingting Yang, Yali Liu, Dingyue Wang, Jiayue Shu, Zhiyuan Liu, Yi Chi, Heming Xu, Dong Xing, Yue Zhou
Journal: Genome biology (2025)
Lebrikizumab Improves Anxiety and Depression Symptoms of Adolescents with Moderate-to-Severe Atopic Dermatitis: Results from a 52-Week, Open-label, Phase 3 Study
Authors: Bob Geng, Vinay Mehta, Amy Paller, Ama Alexis, Alan Irvine, Carsten Flohr, Antonio Torello, Zach Dawson, Evangeline Pierce, Helena Agell, Hong Zhang, Meihua Qiao, Mark Boguniewicz
Journal: Journal of Allergy and Clinical Immunology (2025)
Critical Role of the MNK/eIF4E Pathway in Airway Remodeling in Chronic Allergic Asthma
Authors: Fatemeh Fattahi, Julia Holden, Laura Vallance, Jing Lei, Kareem Hussein, Moamen Shukeir, Kelley Bentley, Marc Hershenson, Ulus Atasoy
Journal: Journal of Allergy and Clinical Immunology (2025)
Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
Authors: John Anderson, Francesco Arcoleo, Emel Aygören-Pürsün, Mauro Cancian, Hugo Chapdelaine, Niall Conlon, Efrem Eren, Mark Gompels, Sofia Grigoriadou, Maria Guarino, Padmalal Gurugama, Tamar Kinaciyan, Markus Magerl, Michael Manning, Marcin Stobiecki, Michael Tarzi, Anna Valerieva, H. James Wedner, William Yang, Andrea Zanichelli, Rafael Crabbé, Susan Mulders, Jonathan Levy, Ulrich Freudensprung, Umar Katbeh, Jochen Knolle, Anne Lesage, Peng Lu, Marc Riedl
Journal: Journal of Allergy and Clinical Immunology (2025)
No Impact Of Concomitant Medication Use On Pharmacokinetic And Safety Profiles Of Garadacimab In Hereditary Angioedema
Authors: Paul Keith, John Anderson, H. Henry Li, Markus Magerl, Regina Treudler, Fiona Glassman, Harsha Shetty, John-Philip Lawo, Maressa Pollen, Timothy Craig
Journal: Journal of Allergy and Clinical Immunology (2025)
Experiences of People Of Color (POC) In The Diagnosis And Treatment Of Chronic Spontaneous Urticaria (CSU) In Los Angeles (LA) And New York City (NYC)
Authors: Donna Gardner, Catherine Blackwell, Elisabeth Bennett, Lesley Gotlib-Conn, Oriana Walker, Karlin Schroeder, Rebekah Park
Journal: Journal of Allergy and Clinical Immunology (2025)
Real-World Attack Rates Before and After Berotralstat Initiation Among Patients with Hereditary Angioedema without C1-Inhibitor Deficiency (HAE-nl-C1-INH) Stratified by Monthly Baseline HAE Attack Frequency
Authors: Mark Davis-lorton, Raffi Tachdjian, Lorena Lopez-Gonzalez, Sean Macknight, Francois Laliberte, Ramya Ramasubramanian, Patrick Gillard, William Lumry
Journal: Journal of Allergy and Clinical Immunology (2025)
Prevalence and Patterns of Dermographism in the Ecuadorian General Population: A Cross-Sectional Study
Authors: Ivan Cherrez Ojeda, Kanokvalai Kulthanan, Gabriela Rodas-Valero, Ana Ochoa-Brito, Juan Achi, Hermenio Lima, Karla Robles-velasco, Leonardo Cano Cevallos
Journal: Journal of Allergy and Clinical Immunology (2025)
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Authors: Michael Manning, John Anderson, Emel Aygören-Pürsün, Laurence Bouillet, Hugo Chapdelaine, Henriette Farkas, Delphine Gobert, Roman Hakl, Joshua Jacobs, Ramon Lleonart, Avner Reshef, Giuseppe Spadaro, Maria Staevska, Marcin Stobiecki, Anna Valerieva, Justin Sun, Li Zhu, Ming Lu, Giorgio Giannattasio, Peng Lu, Marcus Maurer
Journal: Journal of Allergy and Clinical Immunology (2025)
Improvements In Quality-Of-Life In Patients With HAE Receiving Donidalorsen: Post Hoc Analysis From The OASIS-HAE Study
Authors: Danny Cohn, Aaron Yarlas, Jakob Bjorner, Alexandra Feld, Cary Thurm, Laura Bordone, Kenneth Newman, Sabrina Treadwell, Marc Riedl
Journal: Journal of Allergy and Clinical Immunology (2025)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of YH35324, a Novel Long-Acting High-affinity IgETrap-Fc Fusion Protein, in patients with chronic spontaneous urticaria refractory to H1 antihistamines
Authors: Young-min Ye, You Sook Cho, Sook Young Lee, Jung-won Park, Jeong-Hee Choi, Sae-Hoon Kim, Sae Young Lee, Yujeong Shim, Eunji Song, Sujin Sim, Kwan Cheol Pak, Hyeon-Ju Cho, Su Kyung Kim, Myoung Ho Jang, Hae-sim Park
Journal: Journal of Allergy and Clinical Immunology (2025)
An interim analysis of Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for CSU
Authors: Liming Wu, Feng Hu, Ruowen Guo, Liliqiang Ding, Heng Liu, Rongfei Zhu, Xinghua Gao, Yuxiang Zhi
Journal: Journal of Allergy and Clinical Immunology (2025)
Evolution Of Long-Term Prophylaxis In Patients With Hereditary Angioedema With C1 Inhibitor Deficiency, A 10-year Real-Life Experience In A Spanish Cohort
Authors: Jorge Correa-Borit, Monica Colque-Bayona, Rosario Cabañas, Marta Goyanes-Malumbres, Itsaso Losantos, Tatiana Navarro-Cascales, Tamara Pérez-Robles, Elsa Phillips-Angles, Teresa Caballero
Journal: Journal of Allergy and Clinical Immunology (2025)
Comparison of Staphylococcus aureus detection consistency and relationship to pediatric atopic dermatitis outcomes using contact agar plate/culture or metagenomic shotgun sequencing of skin tapes
Authors: Arya Dahal, Wan Chi Chang, Elisabet Johansson, Brittany Grashel, David Morgan, Lindsey Williams, Mindy Hammonds, Seiya Sachdeva, Latha Satish, Jocelyn Biagini, Lisa Martin, David Haslam, Nicholas Ollberding, Gurjit Khurana Hershey
Journal: Journal of Allergy and Clinical Immunology (2025)
Molecular Mimicry as Plausible Explanation of Dupilumab Facial Redness/Dupilumab Facial Dermatitis
Authors: Oscar Correa-jimenez, Alberto Alfaro-Murillo, Gabriela Ivankovich-Escoto, Benjamin Hidalgo-Matlock, Alejandro Palma, Edgardo Chapman, Cindy Arteta-Acosta, Andres Sanchez-Caraballo, Marlon Munera
Journal: Journal of Allergy and Clinical Immunology (2025)
Multiple Proteins Correlate With Tryptase Levels in Patients With Indolent Systemic Mastocytosis (ISM): Preliminary Results of Plasma Proteomic Analysis in PIONEER
Authors: Vito Sabato, Jens Panse, Tracy George, Hussein Abbas, Min Chen, Guang Yang, Rachel Erlich, Benjamin Lampson, Jason Gotlib
Journal: Journal of Allergy and Clinical Immunology (2025)
Remibrutinib Treatment Has No Clinical Impact on Mean Blood Cell Counts in Patients With Chronic Spontaneous Urticaria: Pooled Safety Analysis From REMIX-1 and REMIX-2 Studies
Authors: Giselle Mosnaim, Hugh Windom, Gao Xinghua, Martin Metz, Sarbjit Saini, Atsushi Fukunaga, Alis Burciu, Songqiao Huang, Karine Lheritier, Hichem Zouater, Sibylle Haemmerle, Ana Gimenez-Arnau
Journal: Journal of Allergy and Clinical Immunology (2025)
Long-term Quality of Life and Safety in Patients with Indolent Systemic Mastocytosis Treated with Avapritinib in the PIONEER Study
Authors: Mariana Castells, Cem Akin, Marcus Maurer, Karin Hartmann, Sigurd Broesby-Olsen, Tracy I. George, Erin Sullivan, Ilda Bidollari, Hui-Min Lin, Daniel Shaheen, Frank Siebenhaar
Journal: Journal of Allergy and Clinical Immunology (2025)
Hypoallergenic Der p 2 Mutants Based on the Structure of Allergen-human IgE mAb Complexes
Authors: Anna Pomes, Mohadeseh Asghari, Glorismer Pena-Amelunxen, Alyssa Ball, Kriti Khatri, Jill Glesner, Lisa Vailes, Sabina Wuenschmann, Jian Zhang, Stokes Peebles, Martin Chapman, Scott Smith, Maksymilian Chruszcz, Lorenz Aglas
Journal: Journal of Allergy and Clinical Immunology (2025)
HARBOR: An Ongoing Phase 2/3 Study of Elenestinib in Patients With Indolent Systemic Mastocytosis
Authors: Mariana Castells, Cristina Bulai Livideanu, Olivier Hermine, Vito Sabato, Marcus Maurer, Franziska Ruëff, Stephane Barete, Laurence Bouillet, Jens Panse, Ivan Twose-Alvarez, David González-De-Olano, Renata Cabral, Robert Bird, Karin Hartmann, T.J. Rego, Kevin He, Javier Muñoz-González, Robyn Scherber, Tsewang Tashi, Mar Guilarte
Journal: Journal of Allergy and Clinical Immunology (2025)
A Comparative Evaluation of Quality of Life in Children with Food Allergy Undergoing Oral Immunotherapy (OIT) and Non-OIT Approaches
Authors: Theerameth Pruangmethangkul, Supaluk Tangvalelerd, Kantima Kanchanapoomi, Witchaya Srisuwatchari, Orathai Jirapongsananuruk, Punchama Pacharn
Journal: Journal of Allergy and Clinical Immunology (2025)
Dupilumab Efficacy In Adolescents And Adults With Eosinophilic Esophagitis With And Without Concurrent Elimination Diet: Post Hoc Analysis Of LIBERTY EoE TREET At 52 Weeks
Authors: Antonella Cianferoni, Kathryn Peterson, Eric Low, Changming Xia, Tiffany Pela, Bram Raphael, Juby Jacob-Nara, Amr Radwan
Journal: Journal of Allergy and Clinical Immunology (2025)
Efficacy And Safety of Garadacimab Via Autoinjector/Pre-Filled Pen For Hereditary Angioedema Long-Term Prophylaxis – Interim Results From A Phase 3 Open-Label Extension Study
Authors: Philip Li, F. Ida Hsu, Michael Manning, Henriette Farkas, Constance Katelaris, Avner Reshef, Maressa Pollen, John-Philip Lawo, Harsha Shetty, Timothy Craig
Journal: Journal of Allergy and Clinical Immunology (2025)
Cendakimab Suppresses Type II Inflammatory Biomarkers And Fibrosis Biomarkers In Atopic Dermatitis
Authors: Jie Li, Coryandar Gilvary, Lu Gao, Claudia H.M.C. De Oliveira, Misti Linaberry, Jonathan Silverberg, Sarah Harris
Journal: Journal of Allergy and Clinical Immunology (2025)
Real-World Attack Rates Before and After Berotralstat Initiation Among Patients with Hereditary Angioedema with C1-Inhibitor Deficiency (Type I/II) Stratified by Monthly Baseline HAE Attack Frequency
Authors: Raffi Tachdjian, Mark Davis-lorton, Lorena Lopez-Gonzalez, Sean Macknight, Francois Laliberte, Robert Schell, Patrick Gillard, William Lumry
Journal: Journal of Allergy and Clinical Immunology (2025)
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
Authors: Joshua Jacobs, Adil Adatia, Timothy Craig, Henry Li, William Lumry, Marc Riedl, Karl Sitz, Raffi Tachdjian, Theodora Cohen, Christopher Morabito, Aleena Banerji
Journal: Journal of Allergy and Clinical Immunology (2025)
Very Low Childhood Opportunity Index is associated with increased epithelial inflammation but decreased T2 and Th17 pathway expression in children with Asthma
Authors: Kristen Stenehjem, Samantha Gadd, Leonardo Barrera, Shabnam Elahi, Kyung Jung, Abigail Lang, Jacqueline Pongracic, Leonard Bacharier, Rebecca Gruchalla, Michelle Gill, Gurjit Khurana Hershey, Michael Sherenian, Andrew Liu, George O'Connor, Edward Zoratti, William Sheehan, Stephen Teach, Meyer Kattan, Cynthia Visness, James Gern, William Busse, Amaziah Coleman, Peter Gergen, Patrice Becker, David Jackson, Matthew Altman, Stephanie Lovinsky-desir, Rajesh Kumar
Journal: Journal of Allergy and Clinical Immunology (2025)
Effects of Rilzabrutinib on Angioedema over 12 Weeks: Results from the Phase 2 RILECSU Trial in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria
Authors: Jonathan Bernstein, Chih-Hung Lee, Silvia Ferrucci, Iris Sun, Leda Mannent, Jessica Gereige
Journal: Journal of Allergy and Clinical Immunology (2025)
Enduring Effectiveness and Safety in Patients Newly Treated With Lanadelumab: An EMPOWER Subgroup Analysis
Authors: Daniel Nova Estepan, Raffi Tachdjian, H. James Wedner, Remi Gagnon, M. Dawn Goodyear, John Anderson, Rafael Zaragoza-Urdaz, Hugo Chapdelaine, Paul Keith, Daniel Nova Estepan, Daniel Fox, Natalie Khutoryansky, Aleena Banerji
Journal: Journal of Allergy and Clinical Immunology (2025)
Real-world efficacy of mepolizumab and omalizumab in chronic rhinosinusitis with nasal polyps: Paving the way towards disease control?
Authors: An-sofie Viskens, Laura Bollens, Elien Borgers, Stijn Halewyck, Valérie Hox, Winde Lemmens, Mark Jorissen, Florence Rogister, Kato Speleman, Laura Van Gerven, Olivier Vanderveken, Benedicte Verhaeghe, Anneclaire Vroegop, Peter Hellings
Journal: Journal of Allergy and Clinical Immunology (2025)